Dong-A ST Acquires AbTis and Begins Development of New Antibody Drug Combination
Panoramic view of Donga ST [메디칼업저버 신형주 기자] Dong-A ST begins full-scale development of a new antibody drug combination (ADC), which is attracting the most attention in the global pharmaceutical market. Dong-A ST announced on the 20th that it has acquired AbTis, a company specializing in ADC. Dong-A ST acquired the management rights of Aptis […]
ST Pharm at the Forefront of Technology Export for AIDS Treatment
ST Pharm Receives Inquiries About Technology Export for AIDS Treatment Global Interest in STP0404 Technology Export ST Pharm (237690) has confirmed that it is receiving a deluge of inquiries about its technology export for AIDS treatment. The company’s researchers are currently engaged in research on the treatment. According to ST Pharm, discussions regarding technology export […]
ST Pharm, oligo manufacturing plant passes FDA regular inspection
ST Pharm passed the regular Good Manufacturing Practices (cGMP) inspection of the Banwol Campus, an oligo manufacturing facility, from the U.S. Food and Drug Administration (FDA). [사진=에스티팜] ST Pharm announced on the 25th that its Banwol Campus passed the U.S. Food and Drug Administration’s (FDA) Good Pharmaceutical Quality Management (cGMP) regular inspection and received an […]
Korean Pharmaceutical and Bio Society Announces 2023 Open Innovation Plaza Conference
Korean Pharmaceutical and Bio Society to Host Open Innovation Conference The Korean Pharmaceutical and Bio Society, under the leadership of Chairman Noh Yeon-hong, is pleased to announce the upcoming conference on November 14th at the prestigious Parnas Grand Intercontinental Hotel in Seoul. Titled “2023 Open Innovation Plaza,” this event aims to promote both domestic and […]
Daewoong Acquires Stake in US Partner ‘Privatera’ to Strengthen Global Treatment Business
Daewoong Acquires Stake in US Partner ‘Privatera’ Daewoong Group’s holding company, Daewoong, announced on the 24th that it has obtained 3.46 million shares from its US partner, Privatera Acquisition, for approximately KRW 43.8 billion. This represents 3.4% of Daewoong’s equity capital, bringing its total stake in Privatera to 12.63%. The purpose of this acquisition is […]
